C5AR1 and neoplasm: While neither PMX-53 (a C5aR1 peptide antagonist) nor paclitaxel alone significantly altered tumor progression, a combination of the two synergized to effectively inhibit tumor growth by repolarizing TAMs towards the M1-like phenotype that not only affects angiogenic programs but also leads to recruitment of cytotoxic T lymphocytes [117].